Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply Logica™ across several previously undrugged targets in the RS portfolio.
- Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply Logica™ across several previously undrugged targets in the RS portfolio.
- Logica is an Artificial Intelligence (AI) powered drug solution that translates biological insights into optimized assets.
- “Partnering with the team at Related Sciences, we are excited to deploy Logica in the hunt for first-in-class therapeutics,” said Julie Frearson, PhD, Senior Vice President and Chief Scientific Officer, Charles River.
- Logica is offered as a fully managed, risk-sharing model, with most of the client cost tied to success.